
Matthew A. Gubens, MD, MS, Julia K. Rotow, MD, and Estelamari Rodriguez, MD, MPH, discuss how intracranial activity shapes treatment in ROS1-positive non-small cell lung cancer (NSCLC), a disease with tropism for the brain.

Matthew A. Gubens, MD, MS, Julia K. Rotow, MD, and Estelamari Rodriguez, MD, MPH, discuss how intracranial activity shapes treatment in ROS1-positive non-small cell lung cancer (NSCLC), a disease with tropism for the brain.

Ana I. Velázquez Mañana, MD, MSc, describes how she discusses durability of benefit with patients who have ROS1-positive non-small cell lung cancer (NSCLC) while many trials remain ongoing.

Matthew A. Gubens, MD, MS, Julia K. Rotow, MD, and Estelamari Rodriguez, MD, MPH, discuss how to interpret the single-arm trials supporting ROS1 tyrosine kinase inhibitors in ROS1-positive non-small cell lung cancer (NSCLC).

Estelamari Rodriguez, MD, MPH, Julia K. Rotow, MD, and Ana I. Velázquez Mañana, MD, MSc, explain how they choose among guideline-preferred ROS1 tyrosine kinase inhibitors (TKIs) for first-line treatment of non-small cell lung cancer (NSCLC), in a discussion moderated by Matthew A. Gubens, MD, MS.

Estelamari Rodriguez, MD, MPH, explains why patients with advanced non-small cell lung cancer (NSCLC) and high programmed death ligand 1 (PD-L1) expression should not start immunotherapy while biomarker results are pending, since ROS1-positive disease responds poorly to it.

Julia K. Rotow, MD, explains how RNA-based next-generation sequencing (NGS) fits into testing for newly diagnosed advanced nonsquamous non-small cell lung cancer (NSCLC) in a discussion moderated by Matthew A. Gubens, MD, MS, with panelists Estelamari Rodriguez, MD, MPH, and Ana I. Velázquez Mañana, MD, MSc.

Matthew Gubens, MD, explains how targeted therapies are moving into earlier-stage NSCLC, while molecular testing and resistance profiling guide treatment.

Matthew Gubens, MD, MS, explains how PD-L1 expression, disease burden, and co-mutations guide first-line immunotherapy selection in metastatic non–small cell lung cancer.

October 23rd 2026

October 23rd 2026

October 22nd 2026